Franklin Lakes-based BD on Friday said Michelle Quinn, who currently serves as senior vice president, deputy general counsel and chief ethics and compliance officer, has been named acting general counsel, succeeding Samrat “Sam” Khichi, who will depart BD for a new opportunity, effective Feb. 3.
Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD, and become a member of the Executive Leadership Team.
Before joining BD in 2019, Quinn was vice president and general counsel of North America for Sandoz Inc., a division of Novartis, and, prior to that, served as vice president and associate general counsel at Catalent Pharma Solutions. Quinn holds a Juris Doctor from Villanova University and a Bachelor of Arts in political science from Colgate University.
“Michelle brings more than two decades as a corporate leader and strategic business adviser, and, in the four years since joining BD, she has significantly elevated our legal, ethics and compliance practices,” Polen said. “I’m confident that under her leadership, she will help us advance our BD 2025 strategy as we continue to operate as the more agile and innovative medtech leader we are today. I also want to thank Sam for his significant contributions and his instrumental role in helping shape BD 2025, setting us on the path that is transforming the future of BD. He has made an enormous mark at the company developing and leading teams that have been paramount in driving business-critical work, helping shift our portfolio into transformative spaces and advancing our culture for operating as a best-in-class organization.”
Khichi, 55, is currently general counsel and executive vice president, corporate development, public affairs and regulatory affairs, which he has served as since 2017, when he joined BD through the acquisition of C.R. Bard. Prior to joining BD, Khichi was senior vice president, general counsel and secretary at C.R. Bard. Prior to Bard, he served as senior vice president, chief administrative officer and general counsel for Catalent Pharma Solutions.
As part of the leadership transition, BD also announced that, effective Feb. 3, Ami Simunovich, executive vice president and chief regulatory officer, will report directly to Polen and the public affairs staff will report to Simunovich. In addition, the corporate development unit will report to Chris DelOrefice, executive vice president and chief financial officer, bringing a closer alignment between corporate development and corporate strategy.
